Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Dermatology | Immunology | Family Medicine
Disease Category: Psoriatic Arthritis
Location: United States, MD
Clinical Trial Details
Research Study Summary
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis
Do you have Psoriatic Arthritis? You may qualify to participate in a clinical research study.
Previously approved for the treatment of psoriasis, this agent is now being tested for BOTH biologic naïve as well as biologic exposed patients with psoriatic arthritis with active disease. This trial provides care for 108 weeks for biologic naïve patients and 60 weeks for patients with prior biologic exposure.
To Learn more
Both Male and Female
Date Last Changed:
July 23, 2013
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.